Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic

BIOASIS TECHNOLOGIES (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, and BIOAGILYTIX, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, today announced a strategic collaboration to partner on the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program, Bioasis’ lead candidate to treat HER2+ brain cancer, to investigational new drug (IND) submission and into the clinic.

As quoted in the press release:

“BioAgilytix is a globally-respected leader in immunoassays, and we are tremendously pleased to be working with them on our bioanalytical method development and validation across a number of parameters to support the IND submission and Phase 1 clinical trial for our lead program in HER2+ brain cancer,” said Mark Day, Ph.D., president and chief executive officer, Bioasis. “BioAgilytix’s expertise and experience in large molecule bioanalysis as well as expertise with trastuzumab analytics will be instrumental to advancing this program.”

“We are excited to be working with Bioasis to advance their lead program in HER2+ brain cancer with the xB³ platform technology. We support Bioasis’ mission to aggressively advance this program to bring innovative treatments to patients with brain cancer,” said Jim Datin, president and chief executive officer, BioAgilytix. “We are committed to applying our superior science and expert capabilities – which cover every phase of development, from discovery to global Phase III trials – to achieve Bioasis’ deliverables and timeline, adhering to high quality standards and working collaboratively together as a strategic partner and problem solver.”

Click here to read the full press release.